Introduction {#s1}
============

The concept of immune privilege was first advanced in the 1940s by the Nobel laureate Sir Peter Medawar. While studying tissue transplantation he observed that foreign skin grafts which were normally rejected when transplanted subcutaneously (s.c.), persisted sometimes indefinitely when transplanted into other sites that he termed "immune privileged" (Medawar, [@B68]). One immune privileged site was the anterior chamber (a.c.) of the eye, the aqueous humor (AqH) filled cavity located directly below the cornea and above the lens (Figure [1](#F1){ref-type="fig"}). As the a.c. is separated by a blood--AqH barrier and lacks demonstrable afferent lymphatic drainage, ocular immune privilege was originally explained by sequestration of ocular antigens (Ags) from the circulating immune system. However, seminal findings by Kaplan and Streilein in 1977 which demonstrated that antibody responses were generated to foreign Ags placed in the a.c. (Kaplan and Streilein, [@B42]) clearly showed that the immune system was not ignorant of ocular Ags. We now know that certain immune responses are attenuated or completely excluded from the eye to protect non-regenerating ocular tissues essential for vision. This ocular immune privilege is maintained by unique anatomical and biochemical features of the eye along with the generation of systemic tolerance to ocular Ags which is mediated by regulatory T cells (Treg). In this review we focus on how CD8+ Treg generated during intraocular tumor growth could influence the tumoricidal activity of tumor-specific CD8+ T effector cells.

![**Ocular anatomy and drainage.** Anterior chamber (AC).](fimmu-03-00303-g0001){#F1}

Mechanisms of ocular immune privilege
=====================================

Influence of ocular anatomy on immune privilege
-----------------------------------------------

The absence of afferent lymphatics (Bill, [@B5]), an avascular cornea (Patel and Dana, [@B82]), and tight junctions between vascular endothelial cells in the iris and retina (Crane and Liversidge, [@B14]) are barriers to the generation and expression of ocular immune responses. However, these barriers are not absolute as administration of soluble Ags into the a.c. has been shown to induce Ag-specific CD8+ (McKenna et al., [@B67], [@B64]) and CD4+ (Egan et al., [@B23]; Perez et al., [@B84]) T cell expansion in the ipsilateral submandibular lymph nodes (LNs) and spleens of mice. In addition, activated T cells can enter even a non-inflamed retina to induce uveitis (Xu et al., [@B129]). Therefore, ocular anatomy may increase the threshold for the generation and expression of ocular immune responses but clearly does not prevent them.

Ags encountered within the a.c are thought to exit the eye via the normal drainage of AqH (Bill, [@B5]) (Figure [1](#F1){ref-type="fig"} inset). AqH is continually generated by the ciliary body, fills the a.c., and then primarily drains via the trabecular meshwork and Schlem\'s canal directly into the blood stream. A much smaller percentage of AqH travels by uveal-scleral flow into the cilary muscle and then traverses the choroid and sclera to be drained by conjunctival lymphatics (Bill, [@B5]). As we will discuss in subsequent sections, the spleen is essential for the generation of Treg which also contribute to maintaining ocular immune privilege. Therefore, preferential trafficking of ocular Ags via the bloodstream to the spleen may favor the induction of T cell tolerance. In addition, antigen presenting cells (APCs) from the iris and ciliary body have been shown to selectively traffic to the spleen (Wilbanks and Streilein, [@B126]).

Biochemical barriers to ocular immune responses
-----------------------------------------------

T cells recognize processed peptides presented on major histocompatibility complex (MHC) molecules. In general, peptides presented by MHC Class I molecules are recognized by CD8+ T cells whereas CD4+ T cells recognize peptides complexed with MHC Class II molecules (Figures [2A,B](#F2){ref-type="fig"}). CD8+ T cells differentiate into cytotoxic T lymphocytes (CTL) which primarily eliminate infected or malignant cells by release of lytic granules although cytokines are also released (Figure [2A](#F2){ref-type="fig"}) whereas CD4+ Thelper cells primarily release cytokines to influence other immune cells. For example, during DTH responses, CD4+ T cells express IFNγ and/or IL-17 which recruits and activates macrophages and neutrophils to promote inflammation (Figure [2B](#F2){ref-type="fig"}). The response is delayed due to the requisite time for Ag-specific T cells to expand in draining LN and then migrate to the site of Ag exposure.

![**T cell recognition and response.** Antigen recognition and response by **(A)** CD8+ cytolytic T lymphocytes (CTL) and **(B)** CD4+ T helper cells. Antigen presenting cell (APC), cluster of differentiation (CD), delayed type hypersensitivity response (DTH), T cell receptor (TCR), major histocompatibility complex (MHC), and red blood cell (RBC).](fimmu-03-00303-g0002){#F2}

Although the majority of cells within the body express MHC Class I molecules and can be induced to express MHC Class II molecules by stimulation with interferon gamma (IFNγ), ocular tissues demonstrate atypical expression of MHC Class I and II. For example, corneal endothelial cells express very low levels of MHC Class I which protects these non-regenerating cells from lysis by CD8+ CTL (Abi-Hanna et al., [@B1]). Ocular melanocytes are impaired in expression of MHC Class II which may mitigate CD4+ T cell mediated inflammation (Radosevich et al., [@B87], [@B86]).

AqH contains soluble immune suppressive molecules including cytokines, neuropeptides, and growth factors that have been shown to inhibit adaptive immune responses. Benezra and Sacks documented over forty years ago that AqH could inhibit proliferation of naïve T cells following PHA stimulation (Benezra and Sachs, [@B4]), and we now know that high concentrations of the cytokine TGFβ2 in AqH contributed to this suppression (Kaiser et al., [@B41]; Cousins et al., [@B13]). TGFβ2 is normally present in a latent form within the AqH and elegant work by Masli and coworkers demonstrated a critical role of thrombospondin-1 in activation of latent TGFβ2 to preserve ocular immune privilege (Masli et al., [@B63]).

Taylor and coworkers have clearly shown that AqH directs *in vitro* primed CD4+ T cells away from an IFNγ expressing phenotype and toward a TGFβ1 producing Treg type (Taylor et al., [@B111]). Factors within AqH including TGFβ2 and alpha-melanocyte stimulating hormone (α-MSH) can alone generate Treg (Nishida and Taylor, [@B81]). In combination, α-MSH increases the frequency of Treg by abrogating the anti-proliferative effects of TGFβ (Nishida and Taylor, [@B81]). Additional factors within AqH that favor Treg generation include somatostatin which induces α-MSH production in T cells (Taylor and Yee, [@B113]) and vasoactive intestinal peptide (VIP) which inhibits IFNγ production in effector T cells (Taylor et al., [@B112]).

AqH also contains molecules that inhibit innate immune responses. For example, high concentrations of ascorbic acid in AqH have been shown to inhibit myeloperoxidase activity of neutrophils (Rosenbaum et al., [@B89]) and macrophage migration inhibitory factor (MIF) in AqH inhibits NK cell activity (Apte et al., [@B2]). AqH-mediated changes to the innate immune response also influence the adaptive immune response. For example, pretreatment of macrophages with TGFβ2 decreased their expression of CD40 and IL-12 and increased TGFβ1 expression (Takeuchi et al., [@B110]). Consequently, CD4+ T cells stimulated with TGFβ2 treated APC were deviated from IFNγ producing T cells to TGFβ1 producing Treg (Takeuchi et al., [@B110]; Keino et al., [@B46]).

The interior of the eye is also lined by a continuous layer of pigmented epithelial (PE) cells of the iris, ciliary body, and retina along with the corneal endothelium. All of these ocular tissues have been shown to induce T cells to become immunosuppressive Treg *in vitro* (Sugita et al., [@B108], [@B105], [@B106], [@B109]). Iris PE cells best convert CD8+ T cells into Treg via their expression of CD86 which engages CTLA-4 on activated CD8+ T cells (Sugita et al., [@B105]). In contrast, retinal PE cells and corneal endothelial cells express CTLA-2α which better converts CD4+ T cells into Tregs by decreasing cathepsin-L activity in T cells (Sugita et al., [@B105], [@B106]). Expression of TGFβ1 by CD8+ (Sugita et al., [@B105]) and CD4+ Tregs (Sugita et al., [@B108]) contributes to their immunosuppressive activity. In addition, CD8+ Tregs generated by iris PE express CD86 (Sugita et al., [@B108]) and the immnosuppressive molecule programmed death 1 (PD-1) to suppress CTLA-4+ and PD-1 ligand + T cell effectors (Sugita et al., [@B107]).

Cells lining the interior of the eye also express death inducing molecules including CD95/FasL (Griffith et al., [@B31]), and PD-1 ligand (Hori et al., [@B38]) which can induce apoptosis of effector T cells expressing CD95/Fas and PD-1 respectively. The significance of these death-inducing molecules is very apparent in corneal transplantation as corneal allografts deficient in CD95/FasL (Stuart et al., [@B104]; Yamagami et al., [@B132]) or PD-1 ligand (Hori et al., [@B38]) are rejected with increased frequency. Apoptotic CD4+ T cells were observed at the allograft junction of accepted corneas whereas CD4+ T cells accumulated in rejecting corneal allografts (Hori et al., [@B38]) which supported a death inducing mechanism for these molecules.

Taken together, the above data suggest a model (Figure [3](#F3){ref-type="fig"}) in which activated effector T cells are inactivated by their conversion into Treg as they extravasate from blood vessels and cross epithelial boundaries to enter the eye. Those effectors that escape this regulation may be converted into Treg by immunosuppressive factors within ocular fluids, like AqH, or induced to undergo apoptosis by death inducing molecules within the eye. Again, these barriers to ocular immune responses are not absolute as intravenous transfer of activated effector CD4+ T cells specific for ocular Ags can induce either anterior (Lai et al., [@B56]) or poster uveitis (Xu et al., [@B129]). Similarly, Zhou et al. ([@B135]) recently showed that effector T cells specific for a retinal Ag did not become Treg when injected into the posterior chamber of the eye (Zhou et al., [@B135]). In addition, naïve mice are protected from an ocular tumor challenge if first infused intravenously with tumor-specific CD8+ T effectors (Niederkorn and Streilein, [@B80]). These data clearly indicate that activated effectors can overcome immunosuppressive mechanisms within the eye. Hence, these biochemical barriers must primarily raise the threshold of expression of ocular immune responses.

![**Mechanisms of T cell inactivation within the anterior chamber**.](fimmu-03-00303-g0003){#F3}

Anterior chamber associated immune deviation (ACAID)
----------------------------------------------------

One consequence of stringent control of ocular immune responses is compromised immune mediated elimination of intraocular tumors. For example, certain murine tumor cell lines (Table [1](#T1){ref-type="table"}) that were rejected when transplanted in the skin grew progressively when placed in the a.c. of the eye. Progressive growth of these intraocular tumors was not due to a failure to prime immune responses. Rather, CD8+ CTL (Niederkorn and Streilein, [@B78]; Ksander and Streilein, [@B54]) and cytotoxic antibody responses (Niederkorn and Streilein, [@B76]) specific for tumor Ags were equivalent or greater than those observed in mice that rejected the same tumors in the skin. However, ocular tumor growth also generated immunosuppressive CD8+ Treg that inhibited CD4+ T cell mediated DTH responses to tumor Ags (Streilein and Niederkorn, [@B103]). This unique immune response which was deviated from the conventional immune response observed when tumors were injected in the skin was described by the general term a.c. associated immune deviation or ACAID.

###### 

**Transplantable intraocular tumor models**.

  **Tumor cell line**   **Tumor origin**   **Recipient mouse strain**   **Antigens on tumor**   **Intraocular tumor growth**   **Skin tumor tumor growth**   **References**
  --------------------- ------------------ ---------------------------- ----------------------- ------------------------------ ----------------------------- ----------------------------------
  P815                  DBA/2              Balb/C                       Minor MHC               Progressive                    Rejection                     Niederkorn et al., [@B75]
  P815                  DBA/2              C57Bl/6                      Minor + Major MHC       Rejection                      Rejection                     Niederkorn et al., [@B75]
  B16F10                C57Bl/6            A/J                          Minor + Tumor Ag        Progressive                    Rejection                     Niederkorn and Streilein, [@B79]
  B16F10                C57Bl/6            C57Bl/6                      Tumor Ag                Progressive                    Progressive                   Niederkorn, [@B72]
  E.G7-OVA              C57Bl/6            C57Bl/6                      Ovalbumin               Progressive                    Rejection                     McKenna and Kapp, [@B66]
  Ad5E1                 C57Bl/6            C57Bl/6                      Adenovirus              Rejection                      Rejection                     Schurmans et al., [@B93]
  UV-5C25               C57Bl/6            C57Bl/6                      Tumor Ag                Rejection                      Rejection                     Knisely et al., [@B48]
  P91                   DBA/2              DBA/2                        Tumor Ag                Rejection                      Rejection                     Knisely et al., [@B48]

ACAID has been primarily defined by suppression of DTH responses to Ags that were first encountered in the a.c. and has been demonstrated using tumors (Niederkorn et al., [@B75]), haptenated splenocytes (Waldrep and Kaplan, [@B118]), viruses (Ksander and Hendricks, [@B53]), and soluble Ags (Wilbanks and Streilein, [@B127]). The induction of ACAID is a complicated process which requires several tissues including the eye (Niederkorn and Streilein, [@B77]), spleen (Streilein and Niederkorn, [@B102]), thymus (Wang et al., [@B121]), and sympathetic nervous system (Li et al., [@B58]; Vega et al., [@B115]). The current paradigm for the induction of ACAID (Figure [4](#F4){ref-type="fig"}) suggests that ocular Ags are processed by F4/80+ macrophages that were influenced by TGFβ2 in AqH (Wilbanks et al., [@B123], [@B124]; Wilbanks and Streilein, [@B125]). These APCs travel from the eye via the bloodstream to the thymus and marginal zone of the spleen. Within the thymus CD4− CD8− NKT cells are generated (Wang et al., [@B122]) which migrate to the marginal zone of the spleen via a MIP-2 chemokine gradient created by F4/80+ macrophages from the eye (Faunce et al., [@B24]; Faunce and Stein-Streilein, [@B25]). These F4/80+ macrophages present Ags directly as well as release Ag which is internalized, processed and presented by B cells (D\'Orazio et al., [@B21]). Coordinate interactions between F4/80+ macrophages (Lin et al., [@B59]), B cells (D\'Orazio et al., [@B21]), NKT cells (Sonoda et al., [@B98]; Sonoda and Stein-Streilein, [@B100]), and γδ T cells (Skelsey et al., [@B97]; Xu and Kapp, [@B130]) along with production of IL-10 (D\'Orazio and Niederkorn, [@B22]; Sonoda et al., [@B99]; Ashour and Niederkorn, [@B3]) culminates in the generation of CD4+ and CD8+ Treg which suppress the induction or expression of DTH responses respectively (Streilein and Niederkorn, [@B103]; Wilbanks and Streilein, [@B127]).

![**Paradigm of CD8+ Treg generation in ACAID**.](fimmu-03-00303-g0004){#F4}

The significance of ACAID in ocular immune privilege is clearly demonstrated in splenectomized mice in which ACAID is terminated (Streilein and Niederkorn, [@B102]). Splenectomy prevents the generation of CD4+ and CD8+ Tregs, restores DTH responses to ocular Ags, and promotes spontaneous rejection of immunogenic tumors placed in the a.c. which would otherwise grow progressively (Streilein and Niederkorn, [@B102]). Corneal allografts are also rejected with greater frequency in splenectomized mice (Yamagami and Dana, [@B131]).

CD8+ Treg
---------

T cells function to both eliminate pathogens and to resolve immune responses which, if left uncontrolled, would cause immunopathology and potentially autoimmunity. The seminal experiments by Sakaguchi in 1995 identified that immunosuppressive CD4+ CD25(IL-2Rα)+ T cells protected mice from autoimmunity mediated by CD4+ CD25-- T cells (Sakaguchi et al., [@B90]). These CD4+ Treg represented a distinct lineage generated in the thymus which could be defined by expression of the transcription factor forkhead box P3 (FoxP3) (Fontenot et al., [@B27]). In addition to these "natural Treg," peripheral CD4+ T cells could also be induced to express FoxP3 and demonstrated regulatory activity although FoxP3 negative CD4+ T cells have also been shown to be immunosuppressive (Shevach, [@B94]).

It is important to note that immunosuppressive activity of T cells was first described twenty years earlier by Gershon and Kondo (Gershon and Kondo, [@B29]) who demonstrated that T cells could transfer Ag-specific tolerance to naïve mice. However, their "infectious tolerance" model was mediated by CD8+ T cells. Like CD4+ Treg, both natural and adaptive CD8+ Treg have been described. For example, transfer of natural CD122(common γ-chain receptor)+ CD8+ Treg prevented autoimmunity normally observed in CD122 deficient mice (Rifa\'i et al., [@B88]). In addition, certain treatments (Glatiamer acetate and Fc-ILT3) which mitigate autoimmune conditions are associated with an expansion of induced CD8+ Treg cells (Tennakoon et al., [@B114]; Vlad et al., [@B117]). With the exception of FoxP3, there are no well defined markers that distinguish CD8+ T effector cells from CD8+ Treg cells.

Immune responses to intraocular tumors
======================================

As mentioned previously, certain tumors transplanted in the a.c. of the eye grow progressively despite induction of tumor-specific CTL (Niederkorn and Streilein, [@B78]; Ksander and Streilein, [@B54]). A simple explanation for this phenomenon is that CD8+ CTL do not accumulate within the eye, either because they fail to infiltrate ocular tumors or because they undergo apoptosis within the eye due to ocular expression of death inducing molecules (Griffith et al., [@B31]; Yamagami et al., [@B132]; Hori et al., [@B38]). However, this is clearly not the case as primary uveal melanomas are often infiltrated by CD8+ T cells (de la Cruz et al., [@B18]; Durie et al., [@B22a]; Meecham et al., [@B69]; Ksander et al., [@B52]; McKenna et al., [@B65]). Similarly, CD8+ T cells accumulated within progressively growing tumors transplanted in the a.c. of mice (Ksander et al., [@B51]; Vicetti Miguel et al., [@B116]), and T cells isolated from spleens of mice primed to tumor Ags protected naïve mice from an ocular tumor challenge when transferred intravenously (Niederkorn and Streilein, [@B80]). As transferred T cells influenced tumor numbers within the a.c., these data also indicated that T cells could exert their tumoricidal effector function within the immune privileged eye at least in some circumstances. These data also argue against a conversion of CD8+ CTL into CD8+ Treg within the eye.

Progressive growth of tumors in the a.c. fails to generate CD4+ T cell dependent DTH responses to ocular tumor Ags (Niederkorn and Streilein, [@B78]; Streilein and Niederkorn, [@B103]), and restoration of these DTH responses has been associated with rejection of intraocular tumors. For example, splenectomized Balb/C mice spontaneously eliminated P815 tumors placed in the a.c. and DTH responses to tumor Ags were restored (Streilein and Niederkorn, [@B102]). Similarly, P91 tumors (a P815 variant) induced strong DTH responses when transplanted in the a.c. of syngeneic DBA/2 mice and these intraocular tumors were also rejected (Niederkorn and Meunier, [@B74]). The immunopathological features of intraocular P91 tumor rejection resembled a DTH response as there was neutrophil infiltration, extensive damage to normal ocular tissues (including destruction of the microvasculature), and ischemic bulk necrosis (Knisely et al., [@B48]) resulting in ocular atrophy, termed phthsis. While these data suggested that DTH responses were critical for ocular tumor elimination, additional experiments showed that administration of anti-CD4 antibodies, which abrogated DTH responses measured in the footpad, did not prevent rejection of intraocular P91 tumors (Niederkorn et al., [@B73]). Similarly, we have observed that phthsical rejection of P815 tumors in splenectomized Balb/C mice was not influenced by CD4+ T cell depletion (our unpublished observations). In contrast, CD8 T cell depletion resulted in progressive growth of P815 (our unpublished observation and P91 tumors in the a.c. of DBA/2 mice (Niederkorn et al., [@B73]) although strong P91-specific DTH responses were observed in the footpad (Niederkorn et al., [@B73]). These data indicated that CD4+ T cell mediated DTH responses to tumor Ags were excluded from the eye. More importantly, CD8+ and not CD4+ T cells were most critical for elimination of intraocular P91, or P815 tumors by inducing expression of a "DTH like" immune response within the eye.

The immune suppressive mechanisms that normally exclude CD4+ T cell mediated DTH responses from the eye have not been defined. However, CD4+ T cell infiltration of ocular tumors does not appear to be compromised as Ad5E1 tumors are spontaneously rejected when placed in the a.c. by a process that requires CD4+ T cells, macrophages, and IFNγ (Schurmans et al., [@B93]; Wang et al., [@B120]; Boonman et al., [@B7]; Dace et al., [@B16]). Rejection of these ocular tumors is due to direct effects of IFNγ on tumors as Ad5E1 were also rejected in IFNγ receptor 1 (IFNγR1) deficient mice (Dace et al., [@B15]). As Ad5E1 tumors do not express MHC Class II these data suggest a model in which CD4+ T cells infiltrating ocular tumors express IFNγ only after engaging tumor Ags complexed with MHC Class II that are presented by ocular APC, most probably intratumoral macrophages. The direct effects of IFNγ on Ad5E1 tumors include inhibiting proliferation, and inducing expression of the death inducing molecule TRAIL-R2 and several anti-angiogenic molecules which in combination leads to non-phthsical ocular tumor elimination (Wang et al., [@B120]; Dace et al., [@B15], [@B16]). Interestingly, Coursey and coworkers recently identified an Ad5E1 variant (Clone 2.1) that was rejected in a phthsical manner (Coursey et al., [@B12]). Destructive rejection of these tumors required CD4+ T cells and nitric oxide producing macrophages. TNFα expression was critical for inducing Ad5E1 tumor death in a manner which promoted differentiation of tumoricidal macrophages.

Influence of Treg cells on intraocular tumor growth
---------------------------------------------------

Administration of tumors into the a.c. of the eye induces CD8+ Tregs which transfer suppression of DTH responses to recipient mice (Streilein and Niederkorn, [@B103]). These CD8+ Treg are not generated in splenectomized mice that reject tumors transplanted in the a.c. so it is tempting to speculate that they contribute to progressive intraocular tumor growth. However, it is important to note that these Treg do not inhibit the generation of systemic CD8+ CTL or antibody responses directed against ocular tumors (Niederkorn and Streilein, [@B78]; Ksander and Streilein, [@B54]). Therefore, their immunosuppressive effects could only be at the "efferent" stage of the immune response targeting effector immune cells within primary ocular tumors. This notion is somewhat complicated by the observation that mice bearing progressively growing tumors in one eye reject a subsequent tumor challenge in the opposite eye or skin− a phenomenon termed "intracamerally induced concomitant immunity" (Niederkorn and Streilein, [@B79]; McKenna and Kapp, [@B66]). The induction of CD8+ Treg and CD8+ CTL occur with similar kinetics requiring at least 7--10 days to develop (Streilein and Niederkorn, [@B102]; McKenna and Kapp, [@B66]). Therefore as the second tumor challenge occurred at a time when CD8+ Treg would have already developed these data indicate that Treg do not influence the tumoricidal activity of immune responses within the microenvironment of the subsequent tumor challenge. However, the requirements for rejection of established primary ocular tumors could be different from those necessary to reject subsequent tumor challenges and thus more or less sensitive to immunoregulation. For example, although Ad5E1 tumors are spontaneously rejected in the a.c. of C57Bl/6 mice by a process that requires CD4+ T cells, macrophages and IFNγ (Schurmans et al., [@B93]; Wang et al., [@B120]; Boonman et al., [@B7]; Dace et al., [@B15], [@B16]), IFNγ deficient mice reject Ad5E1 tumors placed s.c. in the skin and these mice also reject a subsequent Ad5E1 challenge in the a.c. (Dace et al., [@B16]). Hence, IFNγ is required for rejection of established Ad5E1 ocular tumors but not for protection from a subsequent ocular tumor challenge.

Tumor burden is also significantly greater in established ocular tumors thereby requiring a stronger immune response to promote tumor elimination which should be more sensitive to immunoregulation. For example, serum or LN cells from mice immunized with P815 tumors s.c. protected naïve mice from an ocular tumor challenge if given 7 days before or at the same time as tumor administration in the a.c. but not if given four days after tumor inoculation (Niederkorn and Streilein, [@B80]). It is important to note that the kinetics and consequences of rejection of intraocular tumors by transferred sera or immune cells were different and significant. Ocular tumors never developed in mice given immune sera and the eye was preserved (Niederkorn and Streilein, [@B80]) suggesting that cytotoxic antibodies immediately eliminated tumors in the a.c. of the eye. In contrast, mice given immune LN cells developed established intraocular tumors which were then rejected by a process that caused phthsis (Niederkorn and Streilein, [@B80]). These data suggest that T cell and macrophage dependent DTH responses were involved in tumor elimination. Therefore, CD8+ Treg could target effector T cells or macrophages within ocular tumors to inhibit expression of DTH responses within the eye and as a result promote ocular tumor growth.

Mechanisms of suppression by CD8+ Treg in ACAID
-----------------------------------------------

Characterization of the immune suppressive activity of CD8+ Treg in ACAID has relied entirely on assays that evaluate the inhibition of DTH responses. Specifically, splenocytes from mice given Ag in the a.c. have been shown to inhibit DTH responses when transferred to recipient mice previously immunized with the same Ag (Streilein and Niederkorn, [@B103]; Wilbanks and Streilein, [@B127]). In addition, splenocytes from mice given Ag in the a.c. were shown to suppress DTH responses when injected into the skin along with Ag and responder splenocytes from mice immunized with the same Ag in adjuvant. In this "local adoptive transfer assay" (LAT), responder cells alone induced DTH responses and these responses were not suppressed by naïve T cells, or splenocytes from mice given Ag s.c. but only by splenocytes from mice given Ag in the a.c. Further experimentation indicated that the splenic regulatory cell was a CD8+ T Cell (Wilbanks and Streilein, [@B127]) and this observation has been very reproducible in several different laboratories (Griffith et al., [@B33]; Nakamura et al., [@B71]; Cone et al., [@B11]; Paunicka et al., [@B83]).

CD8+ Treg isolated from mice given Ag in the a.c. suppress DTH responses in an exquisitely specific manner. For example, splenic CD8+ T cells from mice given bovine serum albumin (BSA) in the a.c. suppress BSA-specific responder cells but not OVA-specific responder cells even if both BSA and OVA Ag are co-injected in the LAT assay to activate BSA-specific CD8+ Treg (Wilbanks and Streilein, [@B127]). These data clearly argue against "linked suppression" in which CD8+ Treg target APC that express both Ags (Kapp et al., [@B44], [@B43]).

The cellular target of CD8+ Tregs and their mechanism of immune suppression in the DTH response have not been fully elucidated. However, in a related system in which CD8+ Tregs were generated after intravenous injection of TGFβ2-treated Ag-pulsed macrophages, these CD8+ Treg inhibited DTH responses by inducing apoptosis of responder T cells through a Fas/FasL dependent mechanism (Kosiewicz et al., [@B49]). Similarly, Griffith and coworkers recently demonstrated that CD8+ Treg generated by the administration of HSV-1, or haptenated splenocytes (TNP-SPL) in the a.c. suppressed DTH responses by an apoptotic mechanism involving TRAIL/DR5 interactions (Griffith et al., [@B30]). In a third system in which CD8+ Treg were generated by injection of haptenated soluble Ag in the a.c., Cone and coworkers also showed that responding T cells were targeted by CD8+ Treg to suppress DTH responses (Cone et al., [@B10]). Recognition of responding T cells by CD8+ Treg was restricted by Qa-1 and not MHC Class I (Cone et al., [@B9]) which was consistent with the requirement for Qa-1 presentation of Ags by B cells in the generation of CD8+ Treg in ACAID (D\'Orazio et al., [@B21]).

CD8+ Treg that recognize T cell receptor (TCR) peptides presented by Qa-1 have been shown to lyse Vβ3+ CD4+ T cells which normally expand in mice given the superantigen staphylococcal enterotoxin A (SEA) (Hu et al., [@B39]). These data suggest that under certain circumstances CD8+ Treg are primed to TCR determinants expressed by responding CD4+ T cells. Recognition of a TCR expressed by CD4+ T cells which expanded to Ags administered in the a.c. would nicely explain the specificity of CD8+ Treg in suppression of DTH responses in ACAID. As previously described, ACAID CD8+ Treg only suppress DTH responses to the same Ag as was originally delivered in the a.c. (Wilbanks and Streilein, [@B127]). Therefore, these data suggest a model in which CD8+ Treg eliminate responding T cell populations by recognizing a unique TCR determinant presented by Qa-1 on T cells (Figure [5A](#F5){ref-type="fig"}). In support of this model two independent laboratories have identified Ag-specific TCR proteins in serum after administration of Ag in the a.c. which transfer tolerance to naïve recipient mice (Ferguson et al., [@B26]; Griffith et al., [@B32]; Hadjikouti et al., [@B34]). In addition, CD8+ Treg which suppress OVA-specific DTH responses can be generated by injection of the class II restricted peptide OVA~323−339~ (Kosiewicz and Streilein, [@B50]) which supports that CD8+ Treg in ACAID are not restricted by MHC Class I and could indicate that CD8+ Treg recognized a TCR determinant expressed by responding OVA~323−339~-specific CD4+ T cells. The inhibition of DTH responses by CD8+ Treg was also associated with absence of immune infiltrates at the site of the LAT assay in the skin which is consistent with elimination of responder T cells (Cone et al., [@B9]).

![**Mechanisms of immunosuppression by CD8+ Treg.** CD8+ Tregs may inhibit DTH responses by inducing apoptosis of CD4+ T cell effectors or macrophages **(A)** or by functionally inactivating these immune populations via TGFb1 expression **(B)**.](fimmu-03-00303-g0005){#F5}

A significant caveat to this model is that CD8+ Treg were also generated in CD4+ deficient MHC Class II−/− mice given soluble Ag in the a.c. (Nakamura et al., [@B71]). Therefore, CD8+ Treg with specificities other than TCR expressed by CD4+ T cells may also be generated. For example, CD8+ OT-I TCR transgenic T cells which recognize OVA peptide 257--264 complexed with Class I K^b^ were induced to become non-lytic CD103+ CD8+ Treg when stimulated with OVA-pulsed-TGFβ2 treated macrophages (Kezuka and Streilein, [@B47]; Keino et al., [@B45]). These OT-I Treg were similar to those observed in ACAID in that they suppressed DTH responses in a LAT assay (Kezuka and Streilein, [@B47]; Keino et al., [@B45]). However, their cellular target may be APC (macrophages and/or dendritic cells) and not responder CD4+ T cells (Figure [5B](#F5){ref-type="fig"}) as Kapp and coworkers showed in a similar system that OT-I Treg reduced expression of the costimulatory molecule, CD86, on dendritic cells (Kapp et al., [@B44]). TGFβ has been shown to reduce costimulatory molecule expression on APC (Takeuchi et al., [@B110]) and is required for the suppressive activity of CD8+ Treg in ACAID (Cone et al., [@B10]; Jiang et al., [@B40]) which could suggest additional non-lytic mechanism for inhibiting DTH responses. However, the suppression of immune responses by non-lytic OT-I CD8+ Treg does not require TGFβ (Kezuka and Streilein, [@B47]; Kapp et al., [@B44]) indicating that other immunosuppressive mediators may be involved. It is important to note that the potential contribution of CD8+ Treg in promoting ocular tumor growth would require their recognition of non-CD4+ T cells because CD4+ T cells do not contribute to elimination of intraocular P91 or P815 tumors (Niederkorn et al., [@B73] and our unpublished observations). Therefore, CD8+ CTL effectors or intratumoral macrophages are logical targets of CD8+ Treg in the ocular tumor microenvironment (Figure [6](#F6){ref-type="fig"}).

![**Potential targets of CD8+ Treg in intraocular tumors**.](fimmu-03-00303-g0006){#F6}

Indirect tumoricidal activity of CD8+ T cells
---------------------------------------------

CD8+ T cells play a critical role in immunosurveillance of tumors by recognition of processed peptides presented by MHC Class I molecules on the tumor cell surface. Through release of cytotoxic granules containing granzyme B and perforin CD8+ CTL directly lyse tumor cells (Simon et al., [@B95]). In addition, CD8+ CTL express IFNγ which can induce apoptosis of certain tumors (Wall et al., [@B119]) and/or influence hematopoietic and non-hematopoietic cells within the tumor microenvironment to affect tumor growth (Blankenstein, [@B6]). For example, IFNγ dependent regression of B16-OVA melanomas transplanted in the skin by CD8+ OVA-specific OT-I T cell effectors required IFNγR1 expression by host cells (Schuler and Blankenstein, [@B92]). An inhibition of tumor angiogenesis preceded tumor regression in other models of IFNγ mediated rejection of tumors by CD8+ T cells suggesting that IFNγ targeted vascular endothelial cells, fibroblasts, and/or pro-angiogenic macrophages (Qin et al., [@B85]).

IFNγ may also promote tumoricidal activity in other immune cell populations within the tumor microenvironment. For example, regression of established E.G7-OVA skin tumors by CD8+ OT-I CTL effectors required IFNγ but not perforin expression by transferred T cells (Hollenbaugh et al., [@B37]; Hollenbaugh and Dutton, [@B36]). IFNγR1 and inducible nitric oxide synthase-2 (NOS2) expression in recipient mice were also required for tumor regression which indicated that CTL-expressed-IFNγ targeted host cells to eliminate skin tumors (Hollenbaugh et al., [@B37]; Hollenbaugh and Dutton, [@B36]). We recently demonstrated that transferred OT-I CTL induced F4/80+ macrophages within E.G7-OVA skin tumors to express tumoricidal concentrations of nitric oxide (NO) (Vicetti Miguel et al., [@B116]). Hence CD8+ T cell elimination of established E.G7-OVA skin tumors was indirect via their induction of tumoricidal activity in intratumoral macrophages. In contrast, established intraocular E.G7-OVA tumors were resistant to OT-I CTL transfer therapy although CTL infiltrated primary intraocular tumors and expressed IFNγ which induced macrophages to express NOS2 protein; the enzyme responsible for NO production. However, ocular tumor associated macrophages did not produce appreciable amounts of NO and were not tumoricidal (Vicetti Miguel et al., [@B116]). Therefore, factors within the immune privileged eye normally inhibit NOS2 enzymatic activity in macrophages which contributes to ocular tumor progression. These data highlight that the interplay between CD8+ T cells and intratumoral macrophages is critical for elimination of intraocular tumors and represents a potential target of CD8+ Treg (Figure [6](#F6){ref-type="fig"}).

Uveal melanoma
==============

Immune suppressive mechanisms, which maintain ocular immune privilege, should theoretically decrease immunosurveillance of intraocular malignancies. However, the most common intraocular tumor, uveal melanoma (UM), is a rare malignancy. The frequency of UM is over 30 times lower than cutaneous melanoma (Singh and Topham, [@B96]; Garbe and Leiter, [@B28]). One explanation for this paradox is that the expression of death inducing molecules within the eye limits tumor outgrowth. For example, tumor necrosis factor (TNF) related apoptosis inducing ligand (TRAIL) is expressed by tissues lining the interior of the eye (Lee et al., [@B57]) and targets transformed cells for apoptosis (Wiley et al., [@B128]). P815 tumor cells transduced to express TRAIL receptor DR5 failed to develop into ocular tumors when injected into the a.c. of the eye of Balb/C mice (Lee et al., [@B57]) which supports this notion. Therefore, the lower frequency of ocular malignancies may be due to augmented expression of death inducing molecules that induce apoptosis in transformed cells. However, when transformed cells become resistant to apoptosis several observations suggest that ocular immune privilege favors tumor growth and persistence.

Uveal melanoma is unique in that primary tumors with an "inflammatory phenotype," characterized by significant infiltration with CD8+ T cells and CD68+ macrophages, are generally larger more vascularized tumors which express a genetic profile indicative of greater risk of liver metastasis (Maat et al., [@B60]). These data suggest that tumor-specific ocular immune responses are somehow converted within the ocular tumor microenvironment to favor tumor growth which is consistent with immunosuppression by ocular immune privilege.

CD8+ T cell function may be impaired within primary uveal melanomas as reduced CD3zeta chain expression, a marker of T cell dysfunction, was observed in T cells infiltrating ocular tumors that ultimately metastasized to the liver (Staibano et al., [@B101]). In addition, T cells isolated from primary uveal melanomas were generally non-responsive, proliferating poorly after stimulation (Ksander et al., [@B52]). In other malignancies reduced CD3zeta chain expression correlated with increased frequencies of activated CD11b+ CD15+ granulocytes in the blood (Schmielau and Finn, [@B91]; Zea et al., [@B134]) and we recently showed that CD11b+ CD15+ granulocytes were increased in a cohort of patients with primary UMs (McKenna et al., [@B65]) suggesting a possible mechanism for CD3zeta chain downmodulation. Although CD8+ T cells within primary UM appear to proliferate poorly, they still accumulate within primary uveal melanomas and indirect evidence suggests that they produce IFNγ. For example, primary UMs with increased numbers of CD8+ T cells are associated with increased HLA expression (de Waard-Siebinga et al., [@B20]) which is known to be influenced by IFNγ (de Waard-Siebinga et al., [@B19]). Moreover, in the E.G7-OVA/C57Bl/6 mouse model of intraocular tumor development we observed that CD8+ T cells which infiltrated intraocular tumors expressed IFNγ at levels which were equivalent to those observed in CD8+ T cells that infiltrated skin tumors (Vicetti Miguel et al., [@B116]).

IFNγ may actually promote immune evasion by ocular tumors as primary uveal melanoma lines treated with IFNγ expressed PD-L1 which inhibited T cell function *in vitro* (Yang et al., [@B133]). Similarly, IFNγ rendered uveal melanoma cell lines resistant to lysis by CD8+ T cells (Hallermalm et al., [@B35]). In addition, IFNγ is required for expression of the suppressive activity of CD8+ Treg in ACAID (Cone et al., [@B11]; Paunicka et al., [@B83]). Therefore, another explanation for primary uveal melanoma growth despite infiltration by CD8+ T cells is that these CD8+ T cells are not tumoricidal effectors but rather immune suppressive Treg.

As previously described the transcription factor FoxP3 faithfully identifies naturally occurring CD4+ Treg in mice and is also expressed in some induced CD4+ and CD8+ Tregs (Shevach, [@B94]). Two studies recently evaluated FoxP3 expression on T cells infiltrating primary uveal melanomas (Lagouros et al., [@B55]; Mougiakakos et al., [@B70]). FoxP3 expression was observed only in CD4+ T cells and their numbers were generally very low and correlated with the size of tumors and frequency of CD3+ T cells (Lagouros et al., [@B55]). As both tumor size and CD3+ T infiltration are negative prognostic indicators (Damato et al., [@B17]), it is difficult to discern the influence of CD4+ FOXP3+ Treg on tumor progression. However, the presence of FOXP3+ Treg in cycloxygenase-2 (COX-2) positive tumors did predict poor survival of uveal melanoma patients (Mougiakakos et al., [@B70]). It is important to note that these studies could not exclude that infiltrating CD8+ T cells, though FoxP3 negative, were immunosuppressive Treg.

Macrophages have also been shown to influence tumor growth (Mantovani et al., [@B62]). For example, macrophages stimulated with IFNγ and LPS, termed M1, demonstrate tumoricidal activity through expression of reactive oxygen and nitrogen production. In contrast, macrophages stimulated with IL-4 and IL-13, termed M2, are not tumoricidal and actually tumor promoting via expression of angiogenic factors including VEGF. Macrophages within primary uveal melanomas express CD163 which is a marker of M2 macrophages (Bronkhorst et al., [@B8]) and primary UMs heavily infiltrated with macrophages are more vascularized (Makitie et al., [@B61]). Taken together these data suggest that ocular tumor associated macrophages may promote tumor growth by inducing tumor angiogenesis. Therefore, it is possible that CD8+ Treg may contribute to ocular tumor growth by maintaining ocular tumor associated macrophages in an M2 phenotype.

Conclusions {#s2}
===========

It is very clear that progressive growth of intraocular tumors generates CD8+ Treg that inhibit CD4+ T cell dependent DTH responses to tumor Ags. However, as restoration of CD4+ T cell responses to tumor Ags does not assure ocular tumor elimination the contribution of CD8+ Treg in ocular tumor progression remains unclear. Interestingly, rejection of certain tumors transplanted into the a.c. of the eye involves a destructive process resembling a "DTH-like" response that requires CD8+ T cells and IFNγ. As several observations indicate that T cell production of IFNγ is not impaired within ocular tumors, CD8+ Treg may target macrophages in progressively growing ocular tumors to prevent their expression of inflammatory mediators that promote DTH responses which destroy the tumor vasculature, and/or directly kill tumor cells (Figure [6](#F6){ref-type="fig"}). One challenge to defining the role of CD8+ Treg in ocular tumor progression is a specific marker that discerns CD8+ CTL effectors from CD8+ Tregs. While the selective expression of CD103 on *in vitro* generated CD8+ Treg is encouraging (Keino et al., [@B45]), *in vivo* expression of CD103 by ACAID CD8+ Treg has not been shown. Future experimentation which compares and contrasts tumor-specific immune responses in splenectomized mice that do not generate CD8+ Treg and eliminate tumors placed in the a.c. to mice with progressively growing intraocular tumors should help to define potential targets for CD8+ Tregs and may identify novel molecules expressed by CD8+ Treg.
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